Empagliflozin restores cardiac function in obese-diabetic HFpEF mice but further alters gene expression - PubMed
4 hours ago
- #cardiac electrophysiology
- #HFpEF
- #SGLT2 inhibitor
- Empagliflozin treatment improves diastolic dysfunction and reduces plasma glucose in obese-diabetic HFpEF mice.
- Chronic empagliflozin treatment normalizes cardiomyocyte electrophysiology and calcium handling.
- Empagliflozin shifts gene expression to a new profile rather than reversing HFpEF-related changes.